linjc16/ctgov huggingface dataset:
Blood Flow MRI for Monitoring Brain Tumors

Study Overview
=================
Brief Summary
-----------------
The investigators are studying the use of an advanced magnetic resonance imaging (MRI) technique for measuring blood flow into brain tumors. This technique does not use radioactive tracers, and it can provide high quality images that can be obtained in a standard MRI scanner.

Detailed Description
-----------------
Our goals are: To compare the blood flow measured with this technique with measures of tumor blood vessel density in pieces of the tumor surgically removed as a normal part of clinical treatment. This will confirm a relationship between the imaging measurements and the microscopic characteristics of tumors. To compare the blood flow in tumors before therapy with the concentration of choline, an indicator of cell proliferation. This choline concentration can be measured with another MRI technique. This information will demonstrate the relationship between cell proliferation and blood supply and will also determine whether the choline measurement adds additional information that is clinically necessary. To determine the reproducibility of blood flow measurements in tumors. This is necessary to better understand the sensitivity of the technique to changes in flow caused by a treatment or changes in tumor vascularity. To monitor changes in blood flow after initial treatment. Since sometimes tumors can reappear, the repeated measures will help determine how useful this new imaging technique is at detecting such recurring tumors.

Official Title
-----------------
Blood Flow MRI for Monitoring of Glioma Angiogenesis

Conditions
-----------------
Brain Tumors

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed with or are suspected of having a glioma Exclusion Criteria: contraindications to MRI which may include the following Pacemaker MRI incompatible metal implant Recently implanted vascular clip History of claustrophobia Metal fragment within the eye Subjects who have received nonstandard therapy may be excluded if the therapy might alter tumor blood flow or other imaging characteristic.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Inflammation and Obesity-associated Disease

Study Overview
=================
Brief Summary
-----------------
Visceral obesity and adipose inflammation is considered a driving force of obesity-related systemic disease, e.g. cardiometabolic disease, liver cirrhosis and chronic kidney disease (CKD). Inflammatory resolution is actively regulated by specialized pro-resolving mediators (SPMs), including the endogenous eicosanoid LXA4. Impairment of SPMs may underlie development of obesity-related pathology.We hypothesize that obese patients who develop obesity-related disease do so because they suffer from impaired endogenous production of pro-resolving lipids. This will result in aggravated adipose inflammation and fibrosis, which contribute to the systemic pathologies. We thus wish to investigate adipose inflammation and the pro-resolving lipid profile of obese subjects with and without obesity associated metabolic disease. We also aim to investigate whether LXA4, LXB4 and other anti-inflammatory agents (such as AICAR) can alter the phenotype of human adipose macrophages in ex vivo tissue culture. We also investigate basic pathways in inflammatory regulation and obesity related cardiometabolic disease.

Official Title
-----------------
Inflammation and Obesity-associated Disease

Conditions
-----------------
Obesity, Inflammation, Kidney Disease, Liver Disease, Metabolic Syndrome, Cardiometabolic Syndrome, Fibrosis

Intervention / Treatment
-----------------
* Procedure: Laparoscopic surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Obese BMI 35-55 kg/m2 Lean BMI 18.5-24.9 Exclusion Criteria: Medical treatment with NSAIDs, corticosteroid treatment, immune-suppressants. Other: smoking, alcohol abuse.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lean healthy controls<br>Healthy controls with BMI 18.5-24.9 Laparoscopic surgery eg cholecystectomy, fundoplication or Heller myotomy and fundoplication or laparoscopic hernia repair. | Procedure: Laparoscopic surgery<br>* Roux-en-Y gastric bypass or other benign laparoscopic surgery<br>|
| Obese<br>Obese BMI 35-55 Laparoscopic Roux-en-Y gastric bypass or Sleeve gastrectomy Phenotype according to cardiometabolic status | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inflammatory status | inflammatory status vs cardiometabolic disease and tissue fibrosis | One year |
Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

Study Overview
=================
Brief Summary
-----------------
Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Official Title
-----------------
A Phase 1, Open-label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

Conditions
-----------------
Hematologic Neoplasms

Intervention / Treatment
-----------------
* Drug: SNX-5422


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >18 years old Karnofsky performance status > 60 confirmed hematological malignancy refractory to available therapy or for which no therapy is available adequate hepatic, renal and hematological function Exclusion Criteria: CNS malignancy at risk for prolonged QT interval significant GI/liver disease other serious concurrent illness or medical condition

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Single Arm<br> | Drug: SNX-5422<br>* dose escalated; tablets every other day; undetermined duration until disease progression<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| adverse events and other safety assessments |  | continuous | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| disease response specific to the hematological malignancy |  | after every 2 cycles | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hematologic Malignancies Hsp90 Hematologic Malignancy
Azithromycin in the Treatment of M. Avium Complex Lung Disease

Study Overview
=================
Brief Summary
-----------------
To determine the safety and efficacy of azithromycin in the treatment of lung infection with M.avium complex and M. abscessus lung disease.

Detailed Description
-----------------
To study the safety and efficacy of azithromycin in combination treatment for M. abscessus and MAC lung disease

Official Title
-----------------
Open, Noncomparative Trial of Azithromycin in the Treatment of M.Avium Complex (MAC) Lung Disease

Conditions
-----------------
Mycobacterium Avium Complex Lung Disease

Intervention / Treatment
-----------------
* Drug: Azithromycin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meet American Thoracic Society criteria for nontuberculous lung disease: two or more AFB smear positive, culture positive sputums or bronchoscopic samples and/or two or more AFB smear negative respiratory samples with moderate to heavy growth (2+-4+); abnormal CXR consistent with M. avium lung disease; abnormal CXR consistent with M. avium lung disease; absence of other lung pathogens (except for the coexistence of M. abscessus). Age 18 and older Pretreatment isolate of M. avium complex available for MIC determination Exclusion Criteria: History of macrolide allergy Received macrolide therapy in last two months Children less than 18 years of age If a menstruating female, not pregnant and on adequate birth control

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Azithromycin<br>Azithromycin combined with 2 other drugs given 3 times weekly for MAc lung disease | Drug: Azithromycin<br>* Azithromycin Daily Dosage dependent on clinical factos such as age, weight and patient specific health descriptors<br>* Other names: Zithromax;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical and microbiological outcomes such as clinical symptoms and laboratory cultures | neg cultures X3( sputum conversion) | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microbiological cultures | culture neg 1 yr on treatment | 1yr | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MAC
Evaluation of an Informative Intervention to the ICU Team About the Presence of Asynchronies in Mechanically Ventilated Patients: Effect Over Incidence Reduction

Study Overview
=================
Brief Summary
-----------------
Mechanical ventilation (MV) if a life-support treatment for critically ill patients that can develop adverse effects. Patient-ventilator asynchronies can be present from the beginning of MV, it can be associated with poor outcome and it can develop clinical changes. The aim of this study is to evaluate if the knowledge of the presence of asynchronies by the healthcare team can help to reduce its incidence, improving outcomes of critically ill patients. A prospective, single-center, before and after study will be conducted in the ICU of Hospital de Sabadell. The study will have 2 phases: a first observational period where the incidence of asynchronies will be assessed, and a second period where a daily information of the presence of asynchronies to the healthcare team will be done with the aim to reduce the incidence. A continous record of asynchronies and clinical variables will be done during ICU stay.

Conditions
-----------------
Asynchronies

Intervention / Treatment
-----------------
* Behavioral: Daily asynchronies information


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Invasive mechanical ventilation < 24 hours. > 18 years-old Exclusion Criteria: > 24 hours of invasive mechanical ventilation at admission. <48 hours of data collected Informed consent not obtained

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Observational group<br> | |
| Other: Group after information intervention<br>Control group after daily information to healthcare team | Behavioral: Daily asynchronies information<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of asynchronies |  | one year |
Histones and Free-plasma DNA After Cardiac Arrest

Study Overview
=================
Brief Summary
-----------------
To evaluate the significance of free-plasma deoxyribonucleic acid (DNA) and plasma histones in cardiac arrest patients.

Official Title
-----------------
Histones and Free-plasma DNA in the Days Following the Cardiac Arrest

Conditions
-----------------
Heart Arrest, Hypothermia, Post Cardiac Arrest Syndrome

Intervention / Treatment
-----------------
* Other: cardiac arrest


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Out of hospital cardiac arrest of presumed cardiac cause Return of spontaneous circulation (ROSC) Glasgow Coma Score < 8 Age > 18 years and < 80 years Exclusion Criteria: >60 minutes from the circulatory collapse to ROSC Time interval > 4 hours from cardiac arrest to initiation of targeted temperature management Terminal illness Coagulation disorder Unwitnessed asystolia Cerebral performance category 3-4 before the cardiac arrest Severe persistent cardiogenic shock Pregnancy Persistent cardiogenic shock (systolic blood pressure < 80 despite inotropic treatment) New apoplexy or intracerebral hemorrhage Lack of consent from the relatives Lack of consent from the general practitioner Lack of consent from the patient if he/she wakes up and is relevant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cardiac arrest patients<br>Patients who has suffered a cardiac arrest | Other: cardiac arrest<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma histones | The level of plasma histones | Approximate 24 hours after cardiac arrest | 
| Free-plasma DNA | The level of total free-plasma DNA | Approximate 24 hours after cardiac arrest | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma histones | The level of plasma histones | Approximate 48 hours and 72 hours after cardiac arrest | 
| Free-plasma DNA | The level of total free plasma DNA | Approximate 48 hours and 72 hours after cardiac arrest |
FLU A+B Nasal Swab Clinical Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this clinical study is to obtain clearance for the nasal swab sample type by demonstrating the performance characteristics of the FLU A+B Test versus standard laboratory culture for Influenza A and B viruses using nasal swab samples.

Detailed Description
-----------------
Patients exhibiting symptoms of influenza enrolled in a fashion that confidentiality of all personal health information is maintained. No patient treatment is affected by enrollment in this trial.

Official Title
-----------------
Evaluation of the RAMP FLU A+B Test Versus Viral Culture Using Clinical Nasal Swab Samples From Patients With Suspected Influenza Infections

Conditions
-----------------
Influenza

Intervention / Treatment
-----------------
* Other: Non-invasive diagnostic testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and Female of all age groups Patients exhibiting influenza symptoms (i.e., fever, body aches, headaches, cough, sore throat, and other respiratory symptoms) at the time of examination Patients must either present with a fever (>100ºF; >37.8ºC) at time of examination or have had a fever (>100ºF; >37.8ºC) or declare at time of the examination that they had a fever within the previous 3 days prior to the examination Must be able to collect sample using the nasal swab sample type Exclusion Criteria: Patients with no fever at time of examination or within the 3 days prior to examination and/or are currently undergoing treatment (including anti-virals) will be excluded from the study.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| all<br>any patient exhibiting symptoms of influenza | Other: Non-invasive diagnostic testing<br>* No patient treatment is altered by enrollment in this trial<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Support the addition of nasal swab sample type to labeling for the FLU A+B Test. The nasal swab sample data will be analyzed for the FLU A+B Test versus standard laboratory culture identification to determine the sensitivity and specificity. |  | 1 day |
Location of GLP-1 Release

Study Overview
=================
Brief Summary
-----------------
Background: Physicians do not have a unified, scientifically tested theory of causation for obesity and its comorbidities, nor do they have explanations for the mechanics of the metabolic/bariatric surgery procedures. Integral to proffered hypotheses are the actions of the hormones glucagon-like peptide (GLP-1), peptide YY (PYY), and leptin. Study objective: To obtain blood levels of GLP-1, PYY, and leptin after stimulation of the terminal ileum and cecum by a static infusion of a food hydrolysate in morbidly obese patients undergoing a duodenal switch procedure. Methods: Plasma levels of GLP-1, PYY, and leptin were obtained at 0, 30, 60, 90, and 120 minutes after instillation of 240 ml of a food hydrolysate into the ileum or cecum.

Official Title
-----------------
Location of Glucagon-Like Peptide (GLP)-1 Release

Conditions
-----------------
Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient who was qualified and approved for bariatric surgery and elected to undergo open duodenal switch procedure. Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cecum<br>Food hydrolysate instilled into terminal cecum of patient undergoing open duodenal switch procedure. Blood samples were then obtained at baseline and at 0, 30, 60, 90, and 120 minutes for analysis of circulating GLP-1, PYY, and leptin. | |
| Ileum<br>Food hydrolysate instilled into terminal ileum of patient undergoing open duodenal switch procedure. Blood samples were then obtained at baseline and at 0, 30, 60, 90, and 120 minutes for analysis of circulating GLP-1, PYY, and leptin. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| GLP-1 | GLP- levels were measured at intervals over two hours after static bowel food hydrolysate was infused, in patients undergoing scheduled open duodenal switch procedure. | 2 hours | 
| peptide YY (PYY) | PYY levels were measured at intervals over two hours after static bowel food hydrolysate was infused, in patients undergoing scheduled open duodenal switch procedure. | 2 hours | 
| Leptin | Leptin levels were measured at intervals over two hours after static bowel food hydrolysate was infused, in patients undergoing scheduled open duodenal switch procedure. | 2 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
GLP-1, PYY, Leptin, Duodenal Switch
Optical Coherence Tomography Angiography Compared to Maternal Doppler in Screening for Hypertension in Pregnancy

Study Overview
=================
Brief Summary
-----------------
Pregnancy related hypertension is one of the most prevalent obstetric complications. The aim of the study is to evaluate the validity and sensitivity of OCT angiography in prediction of pregnancy induced hypertensive disorders in comparison to maternal doppler in the first and second trimesters of pregnancy

Official Title
-----------------
Retinal Microvascular Changes by Optical Coherence Tomography Angiography Compared to Maternal Uterine Artry Doppler in Screening for Hypertensive Disorders in High-risk Pregnancies

Conditions
-----------------
Pregnancy Induced Hypertension

Intervention / Treatment
-----------------
* Diagnostic Test: Optical coherence Tomography Angiography, Uterine artry doppler


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women in the first and second trimesters Exclusion Criteria: pregnant females with associated systemic vascular disease as diabetes, SLE

Ages Eligible for Study
-----------------
Minimum Age: 22 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| case group<br> | Diagnostic Test: Optical coherence Tomography Angiography, Uterine artry doppler<br>* vascular changes in retina by OCT angiography and uterine artry doppler in the first and second trimesters<br>|
| control<br> | Diagnostic Test: Optical coherence Tomography Angiography, Uterine artry doppler<br>* vascular changes in retina by OCT angiography and uterine artry doppler in the first and second trimesters<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| validity and sensitivity of OCT angiography | sensitivity of OCTA in comparison to doppler in prediction of pregnancy related hypertension | 6 months |